HomeAVXT • OTCMKTS
add
AVAX Technologies Inc
$0.00010
Pre-market:(99.00%)-0.000099
$0.00
Closed: Apr 12, 4:24:34 PM GMT-4 · USD · OTCMKTS · Disclaimer
Previous close
$0.00010
Market cap
14.26K USD
Avg Volume
333.00
P/E ratio
-
Dividend yield
-
Primary exchange
OTCMKTS
Market news
About
Avax Technologies, Inc. is a Philadelphia-based biotechnology company whose most advanced product candidate is MVax for melanoma. MVax is a cancer vaccine that received a Special Protocol Assessment agreement with the FDA in October 2006, and subsequently began a Phase III registration clinical trial in November 2007. In previous studies, MVax demonstrated a 5-year overall survival rate of 44% and response rate of 35%. Wikipedia
Founded
1990
Headquarters
Website
Employees
29